{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:24:35Z","timestamp":1783113875393,"version":"3.54.6"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004889","name":"Fondation du CHU de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004888","name":"Centre Hospitalier Universitaire de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.peptides.2026.171466","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:23:50Z","timestamp":1768580630000},"page":"171466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses"],"prefix":"10.1016","volume":"195","author":[{"given":"Ahmed","family":"Sahli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"C.-Gaudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Marceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2026.171466_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2026.171466_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-024-05216-5","article-title":"Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system","volume":"22","author":"Wisniewski","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.peptides.2026.171466_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/597637","article-title":"The effect of bradykinin B2 receptor polymorphisms on the susceptibility and severity of osteoarthritis in a Chinese cohort","author":"Chen","year":"2012","journal-title":"J. Biomed. Biotech."},{"key":"10.1016\/j.peptides.2026.171466_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0195-668X(03)00441-X","article-title":"Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension","volume":"24","author":"Dhamrait","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.peptides.2026.171466_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0196-9781(85)90033-6","article-title":"Competitive antagonists of bradykinin","volume":"6","author":"Vavrek","year":"1985","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2026.171466_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1476-5381.1991.tb12248.x","article-title":"Hoe 140 a new potent and long-acting bradykinin antagonist: in vitro studies","volume":"102","author":"Hock","year":"1991","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/cea.14206","article-title":"The icatibant outcome survey: 10 years of experience with icatibant for patients with hereditary angioedema","volume":"52","author":"Maurer","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.peptides.2026.171466_bib8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.HYP.35.6.1319","article-title":"Antagonist-induced intracellular sequestration of rabbit bradykinin B2 receptor","volume":"35","author":"Houle","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2026.171466_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2026.171466_bib10","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1073\/pnas.91.11.4693","article-title":"The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist","volume":"91","author":"Sawutz","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.peptides.2026.171466_bib11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0022-3565(25)38850-6","article-title":"Effects of peptide and non-peptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin","volume":"269","author":"Marceau","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.peptides.2026.171466_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/sj.bjp.0703764","article-title":"In various tumour cell lines the peptide bradykinin B2 receptor antagonist, Hoe 140 (Icatibant), may act as a mitogenic agonist","volume":"141","author":"Drube","year":"2000","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib13","doi-asserted-by":"crossref","first-page":"25970","DOI":"10.1016\/S0021-9258(18)47145-1","article-title":"Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells","volume":"269","author":"Leeb-Lundberg","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"120","key":"10.1016\/j.peptides.2026.171466_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.bjp.0700955","article-title":"The identification of an orally active, non-peptide bradykinin B2 receptor antagonist, FR173657","volume":"120","author":"Asano","year":"1997","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fphar.2020.00916","article-title":"In vitro pharmacological profile of new small molecule bradykinin B2 receptor antagonists","volume":"11","author":"Lesage","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108523","article-title":"In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development","volume":"105","author":"Lesage","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.peptides.2026.171466_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.peptides.2026.171466_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/ph14030177","article-title":"A robust bioassay of the human bradykinin B2 receptor that extends molecular and cellular studies: the isolated umbilical vein","volume":"14","author":"Marceau","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.peptides.2026.171466_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/mol.52.1.16","article-title":"Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor","volume":"52","author":"Aramori","year":"1997","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib20","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/jm030468n","article-title":"Discovery of the first non-peptide full agonists for the human bradykinin B2 receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks","volume":"47","author":"Sawada","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2026.171466_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/sj.bjp.0704208","article-title":"Proinflammatory characteristics of a nonpeptide bradykinin mimic, FR190997, in vivo","volume":"133","author":"Hayashi","year":"2001","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1476-5381.2009.00409.x","article-title":"Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B2 receptors","volume":"158","author":"Bawolak","year":"2009","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002109900087","article-title":"Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR190997: an in vitro study on human, rabbit and pig vascular B2 receptors. Naunyn-Schmiedeberg\u2019s","volume":"360","author":"Rizzi","year":"1999","journal-title":"Arch. Pharm."},{"issue":"10","key":"10.1016\/j.peptides.2026.171466_bib24","volume":"67","author":"Werner","year":"2015","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.peptides.2026.171466_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1745-6215-10-109","article-title":"The BRAIN TRIAL: a randomised, placebo-controlled trial of a bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury","volume":"10","author":"Shakur","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.peptides.2026.171466_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.952233","article-title":"Treatment of hereditary angioedema\u2014single or multiple pathways to the rescue","volume":"3","author":"Valerieva","year":"2022","journal-title":"Front. Allergy"},{"key":"10.1016\/j.peptides.2026.171466_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1605727","article-title":"Incidental findings related to genes associated to HAE-nC1INH: how to proceed?","volume":"16","author":"Germenis","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.peptides.2026.171466_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2024.03.007","article-title":"Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial","volume":"154","author":"Petersen","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.peptides.2026.171466_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2025.07.033","article-title":"Long-term prophylactic treatment with deucrictibant for angioedema due to acquired C1-inhibitor deficiency","author":"de Lange","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.peptides.2026.171466_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nchembio.2551","article-title":"The molecular basis of subtype selectivity of human kinin G-protein-coupled receptors","volume":"14","author":"Joedicke","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.peptides.2026.171466_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41594-021-00645-y","article-title":"Molecular basis for kinin selectivity and activation of the human bradykinin receptors","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.peptides.2026.171466_bib32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41467-022-28399-1","article-title":"Cryo-EM structures of human bradykinin receptor-Gq protein complexes","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2026.171466_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bcp.2003.09.034","article-title":"Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin recep-tor antagonists","volume":"67","author":"Meini","year":"2004","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1476-5381.2010.01133.x","article-title":"Comparison of the molecular interactions of two antagonists, MEN16132 or icatibant, at the human kinin B2 receptor","volume":"162","author":"Meini","year":"2011","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10822-015-9890-z","article-title":"New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding","volume":"30","author":"Lupala","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.peptides.2026.171466_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/01.RES.88.6.593","article-title":"Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice","volume":"88","author":"Bergaya","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2026.171466_bib37","article-title":"Advent of oral medications for the treatment of hereditary angioedema","volume":"14","author":"Velerieva","year":"2024","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.peptides.2026.171466_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-3565(24)39065-2","article-title":"Metabolism of bradykinin In vivo in humans: identification of BK1\u22125 as a stable plasma peptide metabolite","volume":"294","author":"Murphey","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.peptides.2026.171466_bib39","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.3390\/jcm14165712","article-title":"Bradykinin-mediated angioedema induced by drugs","volume":"14","author":"Suffritti","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.peptides.2026.171466_bib40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1139\/y97-051","article-title":"Antagonistic effects of FR173657 on human, pig, rabbit, and guinea pig kinin receptors: an in vitro study","volume":"75","author":"Rizzi","year":"1997","journal-title":"Can. J. Physiol. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejphar.2005.10.014","article-title":"MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization","volume":"528","author":"Cucchi","year":"2005","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.bjp.0702403","article-title":"Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses","volume":"126","author":"Paquet","year":"1999","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0162-3109(99)00128-9","article-title":"Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist","volume":"43","author":"Pruneau","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.peptides.2026.171466_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1026694732602","article-title":"Effect of icatibant, a bradykinin B2 receptor antagonist, on the development of experimental ulcerative colitis in mice","volume":"44","author":"Arai","year":"1999","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.peptides.2026.171466_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1254\/jjp.90.59","article-title":"Suppression of dextran sulfate sodium-induced colitis in kininogen-deficient rats and non-peptide B2 receptor antagonist-treated rats","volume":"90","author":"Kamat","year":"2002","journal-title":"Jpn. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171466_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2018.03.018","article-title":"Icatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator","volume":"36","author":"Brown","year":"2018","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.peptides.2026.171466_bib47","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.039","article-title":"Icatibant as a potential treatment of life-threatening alteplase-induced angioedema","volume":"27","author":"Cheong","year":"2018","journal-title":"J. Stroke Cereb. Dis."},{"key":"10.1016\/j.peptides.2026.171466_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.33588\/rn.6906.2019123","article-title":"Tratamiento del angioedema orolingual inducido por alteplasa mediante icatibant [Treatment of alteplase-induced orolingual angioedema by means of icatibant]","volume":"69","author":"Mas-Serrano","year":"2019","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.peptides.2026.171466_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16173","article-title":"Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema","volume":"31","author":"Theodorou","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.peptides.2026.171466_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0049-3848(95)00060-5","article-title":"Cleavage of high molecular weight kininogen in ascites and plasma of patients with cirrhosis","volume":"78","author":"Cugno","year":"1995","journal-title":"Thromb. Res."},{"key":"10.1016\/j.peptides.2026.171466_bib51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/cs1010651","article-title":"Bradykinin in the ascitic fluid of patients with liver cirrhosis","volume":"101","author":"Cugno","year":"2001","journal-title":"Clin. Sci. (Lond. )"},{"key":"10.1016\/j.peptides.2026.171466_bib52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.thromres.2007.07.008","article-title":"Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency","volume":"121","author":"Ferguson","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.peptides.2026.171466_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1556\/030.63.2016.1.10","article-title":"Contribution of the kallikrein\/kinin system to the mediation of ConA-induced inflammatory ascites","volume":"63","author":"Baintner","year":"2016","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.peptides.2026.171466_bib54","first-page":"428","article-title":"The bradykinin antagonist Hoe 140 inhibits carrageenan- and thermically induced paw edema in rats","volume":"38","author":"Wirth","year":"1992","journal-title":"Agents Actions Suppl."},{"key":"10.1016\/j.peptides.2026.171466_bib55","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/shk.0b013e3180536124","article-title":"Effects of the bradykinin B2 receptor antagonist icatibant on microvascular permeability after thermal injury in sheep","volume":"28","author":"Jonkam","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.peptides.2026.171466_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/SHK.0000000000000265","article-title":"Alcohol potentiates postburn remote organ damage through shifts in fluid compartments mediated by bradykinin","volume":"43","author":"Chen","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.peptides.2026.171466_bib57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-023-03192-4","article-title":"Bradykinin B2 receptor blockade and intradialytic hypotension","volume":"24","author":"Gamboa","year":"2023","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.peptides.2026.171466_bib58","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaip.2017.03.003","article-title":"Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema","volume":"5","author":"Sinert","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"10.1016\/j.peptides.2026.171466_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jcpt.12997","article-title":"Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: a meta-analysis of randomized controlled trials","volume":"44","author":"Jeon","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.peptides.2026.171466_bib60","article-title":"Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial","volume":"58","author":"I-SPY COVID Consortium","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:41:25Z","timestamp":1777527685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"alternative-id":["S0196978126000033"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171466","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"171466"}}